When was Ferrosa Therapeutics founded?

Ferrosa Therapeutics was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is Ferrosa Therapeutics located?

Ferrosa Therapeutics is headquartered in Switzerland.

Is Ferrosa Therapeutics a funded company?

Ferrosa Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Apr 23, 2026.

When was the latest funding round of Ferrosa Therapeutics?

Ferrosa Therapeutics' latest funding was a $***** Seed round on Apr 23, 2026, with participation from 1 investor. Its primary sector is Hematology. Globally, the Hematology sector has seen $624M in funding in 2026 to date.

Where does Ferrosa Therapeutics rank among its competitors?

Ferrosa Therapeutics ranks 7th amongst 10 active competitors, of which 3 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ferrosa Therapeutics, which secured $3.5M in Apr, 2026.

Who are the top competitors of Ferrosa Therapeutics?

Ferrosa Therapeutics' top competitors include Ensoma, Baoji Pharmaceutical and IMMvention. Among them, Ferrosa Therapeutics secured the most recent funding round in April, 2026.

Ferrosa Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Developer of bispecific antibodies treating anemia associated with chronic inflammation. These biologics target multiple pathways involved in iron regulation and red blood cell production. The therapeutic approach aims to address resistance to existing treatments in patients with kidney disease, cancer, and autoimmune conditions. The molecules are engineered for extended half-life to facilitate infrequent subcutaneous administration.

Website: ferrosatx.com
Email ID: *****@ferrosatx.com

Key Metrics

Founded Year

2026

Location

Switzerland

Stage

Seed

Total Funding

$3.5M in 1 round

Latest Funding Round

Seed, Apr 23, 2026, $*****

Investors

Forty51 Ventures

Ranked

7^th among 10 active competitors

Similar Companies

Ensoma & 8 more

View Ferrosa Therapeutics' full profile

Ferrosa Therapeutics has raised a total funding of $3.5M over 1 round. Its latest funding round was a Seed round on Apr 23, 2026 for $*****. 1 investor participated in its latest round. Ferrosa Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Ferrosa Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 23, 2026	9945524	Seed	8928341	4910326	6832847	3669584

Access funding benchmarks and valuations. Sign up today!

View details of Ferrosa Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ferrosa Therapeutics include Ensoma, Baoji Pharmaceutical and IMMvention. Here is the list of Top 10 competitors of Ferrosa Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ensoma 2019, Boston (United States), Series B	Developer of in vivo hematopoietic stem cell engineering for genomic medicine	$205M	5AM Ventures, Arix Bioscience & 18 others	58/100
2nd	Baoji Pharmaceutical 2019, Baoshan (China), Public	Developer of therapeutics for multiple diseases	$100M	Oriental Fortune Capital, Haitong Securities ... & 2 others	54/100
3rd	IMMvention 2015, Sunnyvale (United States), Series A	Developer of anti-inflammatory therapies for neurodegenerative and cardiometabolic diseases	$8.9M	Carolina Research Ventures Fund, Osage University Partners ... & 3 others	40/100
4th	Kind Pharmaceuticals 2014, Hangzhou (China), Unfunded	Developer of treatments for anemia and other diseases	-	-	24/100
5th	Glycoform 2002, Abingdon (United Kingdom), Unfunded	Developer of therapeutic proteins and glyco-targeted drug delivery systems	-	-	24/100
6th	Canx Unfunded	Developer of therapeutics to address iron related health conditions	-	-	24/100
7th	Ferrosa Therapeutics 2026, Switzerland, Seed	Developer of bispecific antibodies treating anemia associated with chronic inflammation	$3.5M	Forty51 Ventures	23/100
8th	Epifrontier 2025, Pennington (United States), Funding Raised	Developer of epigenetic therapeutics targeting hemoglobinopathies like sickle cell disease	-	Amed	20/100
9th	iron4u 2012, Holte (Denmark), Unfunded	Developer of therapeutics for iron deficiency	-	-	19/100
10th	Suzhou Shengji Pharmaceutical 2014, Suzhou (China), Funding Raised	Developer of glycoprotein hormone drugs for anemia and reproductive health	-	Yuanchuang Duoying Investment Group	15/100